Andreas Argyrides
Stock Analyst at Oppenheimer
(4.53)
# 272
Out of 5,049 analysts
115
Total ratings
53%
Success rate
26.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andreas Argyrides
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Downgrades: Perform | $13 | $20.90 | -37.80% | 3 | Oct 10, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Outperform | $77 → $115 | $82.50 | +39.39% | 2 | Oct 2, 2025 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $26 → $21 | $3.22 | +552.17% | 2 | Oct 2, 2025 | |
| BNTC Benitec Biopharma | Maintains: Outperform | $35 → $29 | $15.78 | +83.78% | 2 | Sep 16, 2025 | |
| KALA KALA BIO | Maintains: Outperform | $15 → $33 | $0.76 | +4,229.00% | 2 | Sep 11, 2025 | |
| SVRA Savara | Maintains: Outperform | $6 → $8 | $4.03 | +98.51% | 1 | Sep 8, 2025 | |
| UTHR United Therapeutics | Maintains: Outperform | $510 → $575 | $447.45 | +28.51% | 1 | Sep 5, 2025 | |
| MNKD MannKind | Maintains: Outperform | $12 → $15 | $6.06 | +147.52% | 2 | Sep 5, 2025 | |
| ABEO Abeona Therapeutics | Maintains: Outperform | $19 → $20 | $4.36 | +358.72% | 2 | Aug 15, 2025 | |
| HRMY Harmony Biosciences Holdings | Assumes: Outperform | $61 | $31.35 | +94.58% | 1 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 → $7 | $6.00 | +16.67% | 5 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $3 | $1.24 | +141.94% | 2 | May 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $13 | $26.42 | -50.79% | 7 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $4 | $2.50 | +60.00% | 5 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $155 → $90 | $32.35 | +178.21% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $9 | $2.38 | +278.15% | 1 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $47 → $15 | $15.65 | -4.15% | 8 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $181 | $197.75 | -8.47% | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $104 | $10.59 | +882.06% | 14 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $4.07 | +1,742.75% | 1 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $2.37 | +279.75% | 8 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $9.05 | +109.94% | 9 | Mar 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $19.33 | +50.03% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $21 | $11.61 | +80.88% | 4 | Feb 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $224 | $18.67 | +1,099.79% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $21.85 | +160.87% | 2 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $7 | $0.72 | +868.32% | 3 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $10 | $0.55 | +1,717.85% | 5 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $70 | $52.80 | +32.58% | 6 | Aug 1, 2023 |
Dyne Therapeutics
Oct 10, 2025
Downgrades: Perform
Price Target: $13
Current: $20.90
Upside: -37.80%
Monopar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $77 → $115
Current: $82.50
Upside: +39.39%
Larimar Therapeutics
Oct 2, 2025
Maintains: Outperform
Price Target: $26 → $21
Current: $3.22
Upside: +552.17%
Benitec Biopharma
Sep 16, 2025
Maintains: Outperform
Price Target: $35 → $29
Current: $15.78
Upside: +83.78%
KALA BIO
Sep 11, 2025
Maintains: Outperform
Price Target: $15 → $33
Current: $0.76
Upside: +4,229.00%
Savara
Sep 8, 2025
Maintains: Outperform
Price Target: $6 → $8
Current: $4.03
Upside: +98.51%
United Therapeutics
Sep 5, 2025
Maintains: Outperform
Price Target: $510 → $575
Current: $447.45
Upside: +28.51%
MannKind
Sep 5, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $6.06
Upside: +147.52%
Abeona Therapeutics
Aug 15, 2025
Maintains: Outperform
Price Target: $19 → $20
Current: $4.36
Upside: +358.72%
Harmony Biosciences Holdings
Jun 2, 2025
Assumes: Outperform
Price Target: $61
Current: $31.35
Upside: +94.58%
Jun 2, 2025
Assumes: Outperform
Price Target: $15 → $7
Current: $6.00
Upside: +16.67%
May 29, 2025
Maintains: Outperform
Price Target: $6 → $3
Current: $1.24
Upside: +141.94%
May 19, 2025
Downgrades: Underperform
Price Target: $13
Current: $26.42
Upside: -50.79%
May 16, 2025
Maintains: Outperform
Price Target: $14 → $4
Current: $2.50
Upside: +60.00%
May 13, 2025
Maintains: Outperform
Price Target: $155 → $90
Current: $32.35
Upside: +178.21%
May 13, 2025
Maintains: Outperform
Price Target: $15 → $9
Current: $2.38
Upside: +278.15%
Jan 17, 2025
Downgrades: Neutral
Price Target: $47 → $15
Current: $15.65
Upside: -4.15%
Nov 15, 2024
Reiterates: Outperform
Price Target: $181
Current: $197.75
Upside: -8.47%
Jun 25, 2024
Initiates: Outperform
Price Target: $104
Current: $10.59
Upside: +882.06%
Jun 25, 2024
Initiates: Outperform
Price Target: $75
Current: $4.07
Upside: +1,742.75%
Jun 25, 2024
Initiates: Outperform
Price Target: $9
Current: $2.37
Upside: +279.75%
Mar 11, 2024
Reiterates: Outperform
Price Target: $19
Current: $9.05
Upside: +109.94%
Mar 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $19.33
Upside: +50.03%
Feb 28, 2024
Reiterates: Neutral
Price Target: $21
Current: $11.61
Upside: +80.88%
Feb 20, 2024
Reiterates: Outperform
Price Target: $224
Current: $18.67
Upside: +1,099.79%
Feb 8, 2024
Reiterates: Outperform
Price Target: $57
Current: $21.85
Upside: +160.87%
Oct 10, 2023
Maintains: Outperform
Price Target: $5 → $7
Current: $0.72
Upside: +868.32%
Aug 11, 2023
Maintains: Outperform
Price Target: $16 → $10
Current: $0.55
Upside: +1,717.85%
Aug 1, 2023
Maintains: Neutral
Price Target: $73 → $70
Current: $52.80
Upside: +32.58%